



Seng H. Cheng, Ph.D.

Title: Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit

Institution: Pfizer

LinkedIn: <https://www.linkedin.com/in/seng-h-cheng>

Biosketch:

Seng H. Cheng, PhD, is Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit at Pfizer. Dr. Cheng obtained his BSc and PhD degrees in Biochemistry at the University of London and trained as a postdoctoral fellow in the field of tumor biology at the National Institute of Medical Research, U.K.

He was Group Vice President of Genetic Diseases Science at Genzyme for 25 years and prior to joining Pfizer, he was the Global Head of Research of Rare Diseases at Sanofi where he led the translational research and clinical development of therapies for patients with rare diseases. Dr. Cheng is experienced in bringing research initiatives from discovery through to early clinical development. He has co-authored 281 research articles and reviews and is a named co-inventor on 62 issued US patents in the area of biotechnology.

As Chief Scientific Officer at Pfizer, he is charged with building upon the foundation of rare disease programs (rare hematologic, metabolic, neurologic, and cardio-renal diseases) that are resident in the Rare Disease Category with emphasis on genetic therapies as an emerging therapeutic paradigm.